Reven Stock

reven.comHealthcare / BioTech & PharmaFounded: 1999Funding to Date: $106.23MM

Reven Pharmaceuticals is a biopharmaceutical company developing solutions for those suffering the effects of vascular and metabolic related diseases.

Register for Details

For more details on financing and valuation for Reven, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Reven.

Register Today

Team

Management Team

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
James Ervin
Chief Technology Officer
Peter Lange
Founder, Board Member & Chief Executive Officer
Henk Van Wyk
Chief Scientist

Board Members

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
Peter Lange
Founder, Board Member & Chief Executive Officer

Other companies like Reven in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Critical Limb Ischemia (CLI) – Major Players Involved in Therapy Development
New Delhi, India -- (SBWIRE) -- 04/09/2018 -- Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities.
The top 15 healthcare deals of 2016
There has been $13.1 billion invested across 1,287 deals so far this year
Updated on: Oct 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.